Insider Aisling Capital Iii Lp Purchased $7.02 million of Loxo Oncology Inc (NASDAQ:LOXO)

Share with your friends


Insider Aisling Capital Iii Lp Purchased $702 million of Loxo Oncology-Transactions

Aisling Capital Iii Lp Insider Buy Transaction

Aisling Capital Iii Lp, known as an insider in Loxo Oncology Inc (NASDAQ:LOXO) , acquired 265,000 shares whose value is estimated to be $7.02 million at average stock price of $26.5. Being a significant transaction, it will probably not go ignored. Aisling Capital Iii Lp presently has rights to 22.45 % of Loxo Oncology Inc’s market cap with ownership of 3.80 million shares.  Dated 19-11-2015 the transaction filing is free at your disposal here.

Loxo Oncology Inc Stock Rating, Sentiment and Fundamentals

Aisling Capital Iii Lp’s investment could mean only one: that it’s confident when it comes to Loxo Oncology Inc’s prospects and its stock price. According to four leading equity analysts that are covering this firm’s earnings potential, there is an expectation of per share earnings of $-1.96 for the 2015 year, which gives Loxo Oncology Inc a price to earnings ratio of NaN.

Rating & Sentiment
PsychSignal Social:SELL
Analysts Rating:BUY
Hedge Funds Sentiment:BUY
Stock Fundamentals
Earnings + FCF Trend:SELL
Sector/Industry Macro:BULLISH
Valuation Models:-
Technical Analysis
ST Trend:UP
MT Trend:UP
LT Trend:UP
OctaFinance Rating*:BUY

* Read How Our Stock Ratings System Works

We rate Loxo Oncology Inc’s stock as buy not only because of the insider transaction by Aisling Capital Iii Lp but also in accordance with OctaFinance’s sophisticated equities time momentum model as shown below. In the last 200 days, the Loxo Oncology Inc’s share price has seen a fast increase of 155.45 % and is now in a very smooth bullish uptrend.

Price Chart of Loxo Oncology NASDAQ:LOXO Stock

Insider Aisling Capital Iii Lp Purchased $702 million of Loxo Oncology-Stock-Price-Chart

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

Based on our analysis and trend model, Aisling Capital Iii Lp’s shareholders equity should advance by a total of $11.80 million USD should the stock price reaches our trading model target of $34.20. Please share with us if you buy the stock of Loxo Oncology Inc by commenting below.

Hedge Funds Ownership

Latest 13F SEC filings show 48 investment managers own shares in Loxo Oncology Inc. The institutional ownership of the company in the last quarter is low, at 86.55 % of the shares outstanding. They increased by 1.06 million the total shares they hold. As of that quarter these funds owned 14.44 million shares. A total of 8 funds opened new positions in Loxo Oncology Inc and 28 increased their holdings. There were 6 funds that closed their positions and 7 that reduced them.

As revealed by SEC’s 13F filings, this company is in Top 10 stock holdings of two [HF3951]. Some of these are: Aisling Capital Llc, Bvf Inc Il.


Dennis Purcell’s Aisling Capital Llc is the most positive institutional investor on Loxo Oncology Inc, with ownership of 3.45 million shares as of Q2 2015 for 9.27% of the fund’s portfolio. Bvf Inc Il is another positive institutional manager owning 1.62 million shares of the company or 5.14% of their stocks portfolio. The stock is also 2.91% of the fund’s AUM. Nea Management Company Llc have 1.69% of their stock portfolio invested in the company for 1.79 million shares. In addition, James E. Flynn’s Deerfield Management Co disclosed it had purchased a stake worth 0.87% of the fund’s stock portfolio in the company. The New York-based fund Orbimed Advisors Llc was also a notable believer in the -listed company, with ownership of 2.18 million shares. Loxo Oncology Inc is 0.33% of the fund’s stock portfolio.

Loxo Oncology NASDAQ:LOXO Company Profile

Loxo Oncology, Inc. is engaged in discovery, development, and commercialization of targeted cancer therapies. LOXO-101 is the Company’s lead product and has completed its pre-clinical research. LOXO-101 is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family. The Company is developing it for the treatment of tumors with TRK alterations. TRK has been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. The Company is conducting Phase 1 clinical trial of LOXO-101, which is an open label, multicenter trial and has two stages: dose escalation and expansion. The objectives of the dose escalation stage are to determine the tolerated dose and the appropriate dose for further clinical investigation, as well as to determine the tolerability and pharmacokinetic profile of orally administered LOXO-101.

Company Website: Loxo Oncology

Currently its market worth is: $525.64 million and it has 16.91 million outstanding shares. As of writing there are 92.36% shareholders and the institutional ownership is 92.36%. The firm has 15 employees. Loxo Oncology Inc was created in Delaware on 2013-05-09. The stock closed at $30.91 yesterday and it had average 2 days volume of 49420 shares. It is up from the 30 days average shares volume of 42271. Loxo Oncology Inc has a one year low of $9.90 and a 250 days high of $32.30. The stock price is above the 200 days SMA. Loxo Oncology Inc last issued its quarterly earnings information on 11/10/2015. The company reported -0.53 EPS for the quarter, missing the consensus estimate of -0.52 by -0.01. The company had a revenue of for 9/30/2015 and for 6/30/2015. Therefore, the revenue was down.

Aisling Capital Iii Lp is also director of Agile Therapeutics Inc, 10 percent owner of Versartis, Inc., T2 Biosystems, Inc., Durata Therapeutics, Inc., Transenterix Inc., Zeltiq Aesthetics Inc.

* The securities are directly held by Aisling Capital III – LP (“Aisling”) – and indirectly held by Aisling Capital Partners III – LP (“Aisling GP”) – as general partner of Aisling – Aisling Capital Partners III LLC (“Aisling Partners”) – as general partner of Aisling GP – and each of the individual managing members and partners (collectively – the “Managers”) of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell – Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer’s Board of Directors. Dr. Joshua Bilenker – the Issuer’s President and Chief Executive Officer – is a member of the Issuer’s Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the “Investment Committee”) of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.

Loxo Oncology - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.